Erratum

Correction

CJASN January 2019, 14 (1) 111; DOI: https://doi.org/10.2215/CJN.12621018

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Liliana Michelle Gomez Mendez, Matthew D. Cascino, Jay Garg, Tamiko R. Katsumoto, Paul Brakeman, Maria Dall’Era, Richard John Looney, Brad Rovin, Leonard Dragone, Paul Brunetta: Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clin J Am Soc Nephrol 13: 1502–1509; published ahead of print August 8, 2018, doi: 10.2215/CJN.01070118.

Due to author error, the Clinicatrials.gov identifier was incorrectly listed in the article as indicated below. The correct trial number identifier is NCT02550652.

“The NOBILITY study is an ongoing phase II trial in subjects with proliferative lupus nephritis randomized to either obinutuzumab or placebo plus background therapy of mycophenolate and steroids (clinicaltrials.gov identifier NCT01905943) that aims to test the hypothesis that greater B-cell depletion can lead to increased rates of response in subjects with lupus nephritis.”

Footnotes

  • Published online ahead of print. Publication date available at www.cjasn.org.

Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Request Permissions
Correction
CJASN Jan 2019, 14 (1) 111; DOI: 10.2215/CJN.12621018
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Recent Tweets about the Article

Keywords